With a focus on addressing commercialization of technologies initiated at - and licensed from - Duke and Ohio State Universities, the initial focus is on developing a therapy that would restore blood flow to the brain during ischemic stroke with the objective of preventing hemorrhage and long-term damage - effectively everaging aptamer technology to improve outcomes in ischemic stroke. The second leading cause of death globally and a leading cause of serious long-term disability, stroke is largely under-treated with only a small percentage of patients provided active intervention rapidly and safely to restore blood flow to the brain and limit neurological damage. Basking Biosciences' lead compound leverages the proven aptamer technology platform developed at Duke to create a highly specific inhibitor of Von Willebrand Factor (VWF) and a paired reversal agent. This paired therapy enables rapid reversibility of DTRI-031âs effect and mitigates the bleeding risk that has limited the adoption of tPA as a thrombolytic in ischemic stroke and derailed many other development programs. VWFâs central role in both clot formation, stabilization and remodeling make it a very attractive target for anti-thrombotic interventi
